.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH06_Gemigliptin.Gemigliptin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH06_Gemigliptin.Gemigliptin| name: | Gemigliptin |
| ATC code: | A10BH06 | route: | oral |
| n-compartments | 2 |
Gemigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in people with type 2 diabetes mellitus. It is an orally administered antidiabetic agent. It has been approved for clinical use in some countries.
Pharmacokinetic parameters reported for healthy adult volunteers following single oral administration.
Noh, YH, et al., & Bae, KS (2012). Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers. Clinical therapeutics 34(5) 1182–1194. DOI:10.1016/j.clinthera.2012.04.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22534255
Choi, HY, et al., & Bae, KS (2014). Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers. Drugs in R&D 14(3) 165–176. DOI:10.1007/s40268-014-0054-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24962635